Key Highlights
- Vanderbilt’s MSI-SEER uses AI to detect hidden immunotherapy-eligible cancer patients missed by standard testing methods
- New AI-powered 3D imaging platform overcomes histology limits, unlocking volumetric insights for oncology and regenerative medicine
- VUMC’s AI breakthroughs mark a strategic leap in precision diagnostics, backed by NIH, DoD, and major global research institutions
AI-Powered MSI-SEER Revolutionizes Tumor Profiling
Vanderbilt University Medical Center (VUMC), in collaboration with Mayo Clinic and leading Asian hospitals, has launched MSI-SEER, an AI model that analyzes pathology slides at the pixel level to detect microsatellite instability-high (MSI-H) regions—key biomarkers for predicting patient response to immune checkpoint inhibitors. Unlike traditional PCR or IHC testing that may overlook heterogenous or focal MSI-H areas, MSI-SEER provides spatially resolved predictions with confidence scoring, allowing oncologists to make better-informed immunotherapy decisions for patients previously deemed ineligible.
Next-Gen 3D Imaging: A Game Changer for AI in Cancer Visualization
In a study published in Nature Communications, VUMC introduced a deep learning-powered 3D tissue imaging platform that redefines how tumors are visualized. The system combines holotomography with AI algorithms to produce subcellular-resolution, hematoxylin- and eosin-equivalent images from tissue sections 10x thicker than traditional histology. This allows for noninvasive, volumetric analysis—a major upgrade over 2D diagnostics—while preserving tissue for downstream spatial omics and genomic profiling. It has transformative applications in oncology, immunology, organ transplant medicine, and biopharma R&D.
Strategic Industry Collaboration and Global R&D Ecosystem
These innovations reflect a multi-institutional synergy between VUMC, Mayo Clinic, Yonsei Severance Hospital, Seoul St. Mary’s Hospital, KAIST, Tomocube Inc., and others, underscoring the global nature of AI innovation in medicine. VUMC’s research was funded by the National Cancer Institute, Department of Defense, and Schmidt Fund for AI, supporting cutting-edge translational work with real-world clinical impact. According to Dr. Tae Hyun Hwang, senior author of both studies, the work sets a new benchmark in merging molecular diagnostics and machine intelligence for high-precision patient care.
AI That Assists, Not Replaces, Clinical Judgment
A key design principle of both platforms is transparency. MSI-SEER provides confidence metrics for each AI-derived prediction, ensuring clinicians can weigh recommendations appropriately. “AI should support—not dictate—medical decisions,” said Dr. Hwang. This human-AI collaboration model represents the future of responsible AI integration in clinical workflows, enabling smarter, safer, and more personalized treatment decisions. The approach also offers parallels to trends seen in HER2-low cancer therapies and could rapidly evolve treatment eligibility standards globally.
About Vanderbilt University Medical Center
VUMC is one of the largest academic medical centers in the U.S., known for its research leadership in oncology, surgery, and biomedical AI. Its cross-disciplinary initiatives, such as the Molecular AI Initiative, are focused on bridging advanced computational science with clinical excellence. With strong institutional and federal funding, VUMC continues to push the frontiers of AI-driven diagnostics and drug development across cancer, immunology, and regenerative medicine.
By
